Raymond James Trust N.A. cut its holdings in shares of Pfizer Inc. (NYSE:PFE) by 2.6% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 574,384 shares of the biopharmaceutical company’s stock after selling 15,492 shares during the quarter. Pfizer accounts for approximately 0.9% of Raymond James Trust N.A.’s holdings, making the stock its 20th biggest holding. Raymond James Trust N.A.’s holdings in Pfizer were worth $21,080,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Corbett Road Capital Management LLC purchased a new position in shares of Pfizer during the second quarter worth approximately $25,000. Reitz Capital Advisors LLC bought a new position in shares of Pfizer in the second quarter worth approximately $29,000. Disciplined Investments LLC grew its holdings in shares of Pfizer by 43.3% in the first quarter. Disciplined Investments LLC now owns 1,148 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 347 shares during the last quarter. Rocky Mountain Advisers LLC grew its holdings in shares of Pfizer by 847.5% in the second quarter. Rocky Mountain Advisers LLC now owns 1,118 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 1,000 shares during the last quarter. Finally, JJJ Advisors Inc. bought a new position in shares of Pfizer in the second quarter worth approximately $44,000. 69.08% of the stock is currently owned by hedge funds and other institutional investors.

In other Pfizer news, Director Ronald E. Blaylock bought 13,000 shares of the company’s stock in a transaction dated Thursday, August 6th. The shares were purchased at an average price of $38.55 per share, for a total transaction of $501,150.00. Following the acquisition, the director now owns 4,000 shares in the company, valued at approximately $154,200. The purchase was disclosed in a filing with the SEC, which is available at this link. Insiders own 0.08% of the company’s stock.

Several research analysts have recently issued reports on the stock. Atlantic Securities cut shares of Pfizer from an “overweight” rating to a “neutral” rating and cut their target price for the stock from $44.00 to $39.00 in a report on Monday, October 12th. Berenberg Bank assumed coverage on shares of Pfizer in a report on Tuesday, September 29th. They issued a “hold” rating and a $38.00 target price on the stock. SVB Leerink raised their target price on shares of Pfizer from $39.00 to $42.00 and gave the stock a “market perform” rating in a report on Wednesday, July 29th. ValuEngine cut shares of Pfizer from a “hold” rating to a “sell” rating in a report on Thursday, July 30th. Finally, Mizuho reiterated a “buy” rating and issued a $43.00 price target on shares of Pfizer in a report on Tuesday, September 15th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and four have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $39.64.

NYSE:PFE opened at $37.95 on Friday. The stock has a market cap of $210.88 billion, a P/E ratio of 15.06, a price-to-earnings-growth ratio of 2.91 and a beta of 0.67. The firm’s fifty day simple moving average is $36.59 and its 200 day simple moving average is $36.32. Pfizer Inc. has a twelve month low of $27.88 and a twelve month high of $40.97. The company has a quick ratio of 1.16, a current ratio of 1.42 and a debt-to-equity ratio of 0.78.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, July 28th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating the Zacks’ consensus estimate of $0.64 by $0.14. Pfizer had a net margin of 28.80% and a return on equity of 25.11%. The firm had revenue of $11.80 billion for the quarter, compared to analysts’ expectations of $11.55 billion. During the same quarter in the previous year, the business posted $0.80 EPS. The company’s quarterly revenue was down 11.0% on a year-over-year basis. On average, analysts expect that Pfizer Inc. will post 2.89 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 1st. Stockholders of record on Friday, November 6th will be issued a dividend of $0.38 per share. This represents a $1.52 dividend on an annualized basis and a dividend yield of 4.01%. The ex-dividend date of this dividend is Thursday, November 5th. Pfizer’s dividend payout ratio (DPR) is presently 51.53%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Featured Article: What are earnings reports?

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.